Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Medical Ethics selects Bayer as New Zealand commercial partner for Tri-Solfen®

Medical Ethics Pty
Posted on: 26 Jul 18

Second country launch for Tri-Solfen®, which is already marketed by Bayer in Australia


An important milestone as the Group continues to expand its international reach and to help minimise suffering associated with wounds



Melbourne, Australia – 26 July 2018 – Medical Ethics Pty Ltd (“Medical Ethics” or “the Group”), a commercial and development company focused on pain mitigation in wounds for humans and animals, announces that its wholly owned subsidiary, Animal Ethics Pty Ltd (Animal Ethics), has signed a long-term, exclusive marketing and distribution agreement with Bayer New Zealand for the Group’s lead product, Tri-Solfen®, in New Zealand for use on animals undergoing painful husbandry procedures.


Tri-Solfen® is designed to adhere to wounds to provide rapid onset numbing with prolonged analgesia effects. The innovative spray and stay topical local anaesthetic and antiseptic gel also contains active ingredients designed to minimise bleeding, protect against infection, coat the wound and promote healing.


The Group successfully registered Tri-Solfen® in New Zealand through the Ministry for Primary Industries, which leads and facilitates the management of animal welfare policy and practice in the country. Tri-Solfen® is initially indicated for use on lambs and calves undergoing husbandry procedures. Under the terms of the agreement, Bayer has the right to market the existing and future indications for all animal species (excluding humans).  The Group will be responsible for applying for additional registrations. 


Derek Bartlett, Managing Director of Bayer New Zealand, commented: 

“At Bayer, we are firmly committed to improving animal wellbeing, especially alleviating the pain and stress of animal husbandry procedures in farm animals. This product goes a long way to achieving that result. Tri-Solfen® is initially indicated for use on lambs and calves, but we are working with Animal Ethics on approvals for further indications and claims. Innovations such as Tri-Solfen® are important for enhancing animal welfare.  We are currently working towards launching to the New Zealand market in early 2019.”


Allan Giffard, Managing Director of Medical Ethics, added:

“We are delighted to announce Bayer as our partner in New Zealand to bring our globally recognised technology to this important country. Bayer’s commitment to improving animal welfare make them the ideal partner in New Zealand and, having already demonstrated the success of our relationship in Australia, we are confident we can continue to help minimise suffering associated with wounds in livestock.  Tri-Solfen® is proven to deliver a highly effective, practical and cost-efficient solution to improve animal welfare outcomes and we look forward to continuing to expand the commercial potential of the product.”


Over one billion livestock globally undergo highly invasive painful husbandry procedures annually. Tri-Solfen® is already registered in Australia for sheep and cattle husbandry procedures, where it has been marketed and distributed by Bayer since its launch in 2005. To date, Tri-Solfen® has been used to successfully treat over 80 million animals undergoing routine surgeries in the Australian livestock industries. The global market potential for Tri-Solfen® is estimated to be in excess of AUD $350 million per year for the treatment of routine on farm procedures in calves, lambs and piglets.


Animal Ethics accelerated the expansion of its global registration programmes in 2017 through a commercial partnership with Dechra Pharmaceuticals PLC (Dechra), a FTSE 250 international veterinary pharmaceutical business. As part of the partnership, Dechra became a cornerstone investor in Medical Ethics and, in a separate agreement with Animal Ethics, secured the global licensing rights (excluding Australia and New Zealand) for the Group’s proprietary platform technology in animals. Dechra will support the Group’s strategy to register Tri-Solfen® in major international markets.  As such, the Group submitted a regulatory dossier to the European Medicines Agency in June 2018 to register Tri-Solfen® in Europe for painful husbandry procedures in piglets and dairy calves.

Editor's Details

Mike Wood

Last updated on: 26/07/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.